[Chemotherapy associating mitomycin C, thiotepa and vindesine in advanced breast cancers. Study of 100 cases (author's transl)].
One hundred patients suffering from advanced breast cancers and resisting to one (15) or several (85) drugs previously administered have been treated by an association of mitomycin C, thiotepa and vindesine, given every 3 weeks. Toxic effects were frequently observed and it was necessary to stop the treatment in more than 25 p. cent of the patients. Hemorrhagic complications due to thrombopenia (50 p. cent of cases) were severe in few cases and were responsible for the death of 2 patients. An overall objective response has been obtained in 41 cases and a regression in more than 50 p. cent of the lesions with a median duration of 7.5 months has been observed in 15 cases. The most striking effects have been noted in lymph nodes and skin involvement with an appreciable effect on the functional (subjective) and painful syndrome in 60 p. cent of cases. Difficulties in applying this chemotherapy to patients who had already been heavily treated explain a toxicity which would probably be reduced by an earlier application of the treatment. The quality of the results obtained (here) with these patients incite to study the effect of this association primarily to improve the long-term prognosis of localized or already disseminated breast cancers.
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000556:secondary; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin; D008937:Mitomycins / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D013852:Thiotepa / Q000009:adverse effects / Q000627:therapeutic use*; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives; D014751:Vindesine
D000970:Antineoplastic Agents; D008937:Mitomycins; D016685:Mitomycin; D014747:Vinblastine; D013852:Thiotepa; D014751:Vindesine
Chimiothérapie associant mitomycine C, thiotépa et vindésine dans les cancers mammaires en phase avancée. Etude d'une série continue de 100 cas.